VIR (Vir Biotechnology, Inc.) Stock Financials & Earnings | Market Cap Arena

VIR (Vir Biotechnology, Inc.) Stock Financials & Earnings | Market Cap Arena

VIRVir Biotechnology, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$69M

Net Income (TTM)-$438M

EPS (TTM)-$3.16

Free Cash Flow (TTM)-$392M

Gross Margin100.0%

Op. Margin-682.7%

Net Margin-638.9%

FCF Margin-571.5%

P/S Ratio (TTM)20.3x

P/E Ratio (TTM)—

YoY Rev Growth-7.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$63M	-$97M	-$143M
Q2 23	$4M	-$164M	-$215M
Q3 23	$3M	-$142M	-$187M
Q4 23	$17M	-$90M	-$139M
Q1 24	$56M	-$42M	-$80M
Q2 24	$3M	-$102M	-$159M
Q3 24	$2M	-$193M	-$231M
Q4 24	$12M	-$76M	-$117M
Q1 25	$3M	-$115M	-$140M
Q2 25	$1M	-$96M	-$118M
Q3 25	$240K	-$151M	-$173M
Q4 25	$64M	$431M	-$37M

Valuation

Quarter	P/S	P/E
Q1 23	3.1x	—
Q2 23	2.8x	—
Q3 23	11.7x	—
Q4 23	16.1x	—
Q1 24	17.5x	—
Q2 24	17.6x	—
Q3 24	17.7x	—
Q4 24	18.7x	—
Q1 25	66.7x	—
Q2 25	73.2x	—
Q3 25	82.5x	—
Q4 25	20.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$126M	-$133M
Q2 23	-$389M	-$399M
Q3 23	-$156M	-$160M
Q4 23	-$108M	-$109M
Q1 24	-$109M	-$111M
Q2 24	-$78M	-$79M
Q3 24	-$171M	-$174M
Q4 24	-$88M	-$90M
Q1 25	-$78M	-$80M
Q2 25	-$120M	-$123M
Q3 25	-$168M	-$168M
Q4 25	-$26M	-$21M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$7M
Q2 23	$9M
Q3 23	$4M
Q4 23	$2M
Q1 24	$2M
Q2 24	$666K
Q3 24	$2M
Q4 24	$2M
Q1 25	$2M
Q2 25	$3M
Q3 25	$317K
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-94.9%	-5.6%
Q2 23	+109.3%	+18.6%
Q3 23	-99.3%	+5.4%
Q4 23	-66.0%	-22.1%
Q1 24	-10.5%	-33.9%
Q2 24	-19.0%	-26.2%
Q3 24	-9.8%	+23.4%
Q4 24	-26.3%	-16.9%
Q1 25	-94.6%	+4.5%
Q2 25	-60.5%	-26.0%
Q3 25	-89.9%	-25.7%
Q4 25	+417.8%	-22.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$0	0.0%
Q1 24	$0	0.0%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$16M	128.0%
Q1 25	$14M	463.7%
Q2 25	$12M	1025.6%
Q3 25	$0	0.0%
Q4 25	$23M	35.2%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$158M	—
Q2 23	$168M	—
Q3 23	$145M	—
Q4 23	$109M	—
Q1 24	$100M	—
Q2 24	$105M	—
Q3 24	$195M	—
Q4 24	$106M	—
Q1 25	$119M	—
Q2 25	$98M	—
Q3 25	$151M	$22M
Q4 25	$88M	$24M

Revenue Segments

Quarter	Contract Revenue	Grant	Collaboration Revenue
Q1 24	$52M	$5M	—
Q2 24	$886K	$2M	$55K
Q1 25	$2M	$1M	—

Revenue by Geography

Quarter	Non-US	United States
Q1 25	$2M	$1M
Q4 25	$61M	$310K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$825M	$1.4B	$2.3B
Q2 23	$667M	$1.2B	$1.8B
Q3 23	$452M	$1.2B	$1.7B
Q4 23	$242M	$1.3B	$1.5B
Q1 24	$161M	$989M	$1.1B
Q2 24	$297M	$854M	$1.2B
Q3 24	$168M	$746M	$914M
Q4 24	$223M	$682M	$905M
Q1 25	$274M	$528M	$802M
Q2 25	$211M	$395M	$606M
Q3 25	$170M	$336M	$507M
Q4 25	$234M	$229M	$463M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	134M	+0.3%
Q2 23	134M	+0.4%
Q3 23	134M	+0.2%
Q4 23	135M	+0.2%
Q1 24	135M	+0.5%
Q2 24	136M	+0.7%
Q3 24	137M	+0.3%
Q4 24	137M	+0.1%
Q1 25	137M	+0.5%
Q2 25	138M	+0.7%
Q3 25	139M	+0.3%
Q4 25	139M	+0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 17	—	—
FY 18	—	—
FY 19	$3K	229
FY 20	$206K	327
FY 21	$2M	444
FY 22	$3M	576
FY 23	$147K	587
FY 24	$182K	408
FY 25	$187K	367